Physician

Mark Levitan, MD

According to 2025 Medicare claims, Mark Levitan, MD (NPI: 1609848399) practices ophthalmology in the Austin-Round Rock-San Marcos, TX market, with the plurality of this provider's patient population coming from Travis, TX. This provider's primary affiliated billing organization is AUSTIN RETINA ASSOCIATES PLLC (NPI: 1114999828; TIN: 74-2034080) and primary practice location at 78705-1169.

Levitan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 945 traditional Medicare patients, billed 21,319 HCPCS/CPT codes, and received $2,976,772 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 83 prescription claims across 44 beneficiaries totaling $8,215 in drug costs, led by Ketorolac Tromethamine (Ketorolac Tromethamine). Open Payments data shows 9 records totaling $995. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,786,710 to $2,976,772. In contrast, Part D prescription costs have fallen sharply in recent years, from $19,653 to $8,215. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.9M$3.9M2015 Medicare payment: $1,786,710 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $2,275,028 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $2,391,441 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,520,772 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $3,219,923 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $3,458,226 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $3,882,449 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $3,362,208 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,640,263 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,976,772 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,17512,714$1,786,710
20161,27113,357$2,275,028
20171,34812,948$2,391,441
20181,34913,825$2,520,772
20191,43915,170$3,219,923
20201,36114,281$3,458,226
20211,32215,684$3,882,449
20221,25613,215$3,362,208
202390613,122$2,640,263
202494521,319$2,976,772

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$15K$30K2015 Drug cost: $19,653 (USD; Tot_Drug_Cst)2016 Drug cost: $18,595 (USD; Tot_Drug_Cst)2017 Drug cost: $29,682 (USD; Tot_Drug_Cst)2018 Drug cost: $26,348 (USD; Tot_Drug_Cst)2019 Drug cost: $22,594 (USD; Tot_Drug_Cst)2020 Drug cost: $25,364 (USD; Tot_Drug_Cst)2021 Drug cost: $20,262 (USD; Tot_Drug_Cst)2022 Drug cost: $17,204 (USD; Tot_Drug_Cst)2023 Drug cost: $5,698 (USD; Tot_Drug_Cst)2024 Drug cost: $8,215 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201591190$19,653
201681161$18,595
201798247$29,682
201892230$26,348
2019101253$22,594
202086217$25,364
202187182$20,262
202267125$17,204
20233782$5,698
20244483$8,215

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg2161,894$654
92235Exam of retinal blood vessels using a special camera after injection of a dye395836$126
67028Injection of drug into eye3871,448$103
92014Established patient complete exam of visual system448555$89
92134Imaging of retina7821,985$29

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Ketorolac TromethamineKetorolac Tromethamine251,381$960

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.9$995ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Mark Levitan, MD?

Tedicare shows public-source Medicare data for Mark Levitan, MD (NPI 1609848399), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Levitan, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Levitan, MD?

Mark Levitan, MD is linked to AUSTIN RETINA ASSOCIATES PLLC (billing NPI 1114999828) in the available physician profile data.

Does Mark Levitan, MD have Open Payments data?

Mark Levitan, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.